New Research
New research just published looking at surgery vs medications for weight loss.
While some have suggested that potent GLP-1 therapies may replace surgery, the findings from the M6 study highlight substantial benefits including a survival advantage associated with metabolic surgery, even in the era of GLP-1 medications.
At the end of the study, patients who underwent surgery had:
-
32% lower risk of death
-
35% lower risk of major adverse cardiovascular events (MACE), such as heart attack, heart failure, or stroke
-
47% lower risk of CKD
-
54% lower risk of retinopathy
The GLP-1 RA medications used in the nonsurgical group during follow-up included:
-
Liraglutide (65.4%)
-
Dulaglutide (48.6%)
-
Exenatide (32.5%)
-
Semaglutide (26.5%)
-
Tirzepatide (4.4%)
-
Lixisenatide (2.9%)
Patients in the nonsurgical group lost an average of 6.8% of their body weight which was less than the 9.6% reported in the STEP-2 trial with semaglutide in people with type 2 diabetes.
Book an Appointment
Make the first step in your weight loss journey. Found out how to reach us by clicking below. Or simply just ring us.
Book an Appointment